

PATENT
Docket No. SALK1650-2
(088802-2753)

Sub. 15

E3

20. (New) A method according to claim 18 wherein said modulating glucose metabolism results in decreased gluconeogenesis.
21. (New) A method according to claim 20 wherein transcription of PEPCK is inhibited.
22. (New) A method according to claim 20 wherein transcription of the glucagon gene is inhibited.
23. (New) A method according to claim 18 wherein said individual is a human.
24. (New) A method according to claim 18 wherein said contacting is accomplished by oral, intravenous, subcutaneous, intramuscular or intracutaneous mode of administration.

II. REMARKS

The presently claimed invention offers novel and nonobvious methods for treating individuals with diabetes mellitus by inhibiting the interaction between the cAMP responsive transcriptional activator CREB and CBP, a protein that binds to the phosphorylated (i.e., activated) form of CREB and mediates cAMP responsive transcription. Also claimed are methods to select such inhibitors.

Prior to the present communication, claims 1-7, 12 and 17 were pending. By this communication, claims 5 and 7 have been amended and claims 18-24 have been added to define Applicant's invention with greater particularity. The amendments and new claims submitted herewith do not introduce new matter or require a new search. The claims are fully supported by the specification and original claims. Thus, claims 1-7, 12, 17 and 18-24 are currently pending in this application.

PATENT
Docket No. SALK1650-2
(088802-2753)

III. SUMMARY

It is respectfully submitted that the application is in condition for allowance. Accordingly, reconsideration and favorable action on all the claims is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 50-0872. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Date 1/23/03

By SE E. Reiter

Stephen E. Reiter
Attorney for Applicant
Registration No. 31,192

FOLEY & LARDNER
Customer Number: 30542



30542

PATENT TRADEMARK OFFICE

Telephone: (858) 847-6711
Facsimile: (858) 792-6773

PATENT
Docket No. SALK1650-2
(088802-2753)

CLAIM AMENDMENTS

5. (Twice Amended) A method according to claim 2 wherein transcription of the glucagon gene is inhibited.

7. (Amended) A method according to claim 1 wherein said contacting is [carried] accomplished by oral, intravenous, subcutaneous, intramuscular or intracutaneous mode of administration.